Total metabolic lesion volume of lymph nodes measured by 18F-FDG PET/CT: a new predictor of macrophage activation syndrome in adult-onset Still’s disease

Table 5 The AUC, sensitivity, specificity, and likelihood ratio of PET/CT parameters, serologic markers, and systemic scoring for predicting the occurrence of MAS

Factor	AUC (95% CI)	Cutoff value	Sensitivity, % (95% CI)	Specificity, % (95% CI)	Likelihood ratio
IL-2R	0.899 (0.776–0.999)	2824 pg/ml	75.0 (40.9–95.6)	97.3 (48.7–99.9)	27.8
MLV_total of LNs	0.855 (0.642–0.999)	62.2	80.0 (37.6–99.0)	93.9 (80.4–98.9)	13.2
SUV_max of the spleen	0.765 (0.630–0.900)	3.55	100.0 (67.6–100.0)	53.1 (39.4–66.3)	2.13
Systemic score ≥ 7	0.713 (0.541–0.885)		87.5 (52.9–99.4)	55.1 (41.3–68.1)	1.95
Ferritin > 5 ULN	0.642 (0.455–0.828)		87.5 (52.9–99.4)	40.8 (28.2–54.8)	1.48

LN lymph node, MLV metabolic lesion volume, IL-2R interleukin-2 receptor, MAS macrophage activation syndrome. MLV_total of LNs were calculated from the patients with hypermetabolic lymph nodes (n = 38)

ISSN: 1478-6362